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Background and aim: This study proposed a method to estimate the beam-on time for prostate
cancer patients treated on Tomotherapy when FW (ﬁeld width), PF (pitch factor), modulation
factor (MF) and treatment length (TL) were given.
Material and methods: The study was divided into two parts: building and verifying the model.
To  build a model, 160 treatment plans were created for 10 patients. The plans differed in
combination of FW,  PF and MF. For all plans a graph of beam-on time as a function of TL was
created and a linear trend function was ﬁtted. Equation for each trend line was determined
and  used in a correlation model. Finally, 62 plans veriﬁed the treatment time computation
model – the real execution time was compared with our estimation and irradiation time
calculated based on the equation provided by the manufacturer.
Results: A linear trend function was drawn and the coefﬁcient of determination R2 and the
Pearson correlation coefﬁcient r were calculated for each of the 8 trend lines correspond-
ing  to the adequate treatment plan. An equation to correct the model was determined to
estimate more accurately the beam-on time for different MFs. From 62 veriﬁcation treat-
ment plans, only 5 disagreed by more than 60 s with the real time from the HT software.
Whereas, for the equation provided by the manufacturer the discrepancy was observed in16  cases.
Conclusions: Our study showed that the model can well predict the treatment time for a given
TL,  MF, FW and it can be used in clinical practice.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All.  Background
elical Tomotherapy (HT) is one of the novel approaches
hat enable intensity-modulated radiation therapy (IMRT)
elivery technique. HT can provide a high conformity and
omogeneity at the target volume and at the same time spare
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organs at risk (OAR).1–7 This is achieved by a different dose
delivery in reverse to a classic linear accelerator.8 In HT, the
gantry rotates in a helical manner around the patient, while
the couch moves toward the gantry. Fan beam is modulatednd Cancer Centre, Garbary 15, 61-866 Poznan, Poland.
by a binary multileaf collimator that generates an enormous
number of beam elements that irradiate the target volume.9,10
Treatment planning parameters in HT, namely ﬁeld width
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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(FW), pitch factor (PF) and modulation factor (MF), are also
different. They are chosen individually for each treatment
plan, based on the shape and volume of the planning target
volume (PTV). Moreover, those parameters inﬂuence not only
the dose distribution but also the beam-on time.11
FW determines the size of the beam in the longitudinal
axis and can have three discreet values: 1.05, 2.5 and 5 cm.  The
larger FW, the worse dose gradient in cranial–caudal direction
but the shorter beam-on time.
PF is deﬁned as the axial couch distance traveled for one
gantry rotation divided by FW.12 Contrary to the helical com-
puted tomography (CT), in HT the PF should be less than 1.
Another aspect worth considering when choosing PF is the
thread effect. This effect occurs due to the helical junctioning
of the divergent fan beam used in HT. Kissick et al.12 proposed
a solution to minimize the thread effect. They suggested to use
a PF of 0.86/n, where n is an integer. The more  complex PTV,
the lower PF should be used to sculpt the dose distribution in
the cranial–caudal direction.
MF is deﬁned as the ratio of the maximum leaf open time
to the mean leaf open time for all non-zero projections.13 It
modulates the beam by limiting leaf open times. Higher MF
increases the spectrum of beam modulation; however, it also
increases the beam-on time.
In routine practice, the quality of dose distribution is very
important.14–16 The aim is always to spare OARs and at the
same time to irradiate the target volume very conformally
and homogeneously.17 However, the treatment time is also a
very important issue.18 Prolonged beam-on time inﬂuences
patient’s comfort and increases the possibility of intra- and
inter-fraction movements. Another important issue is that it
decreases the number of patients irradiated per day. Taking
all these facts into account, we  usually have to make com-
promise between the quality of the treatment plan and the
treatment time. It has been shown11 that for prostate cancer
patients the most optimal treatment planning parameters are:
FW = 2.5, PF = 0.215, MF  = 2.5. However, the MF value of up to 3.5
may also be considered.
Treatment time depends not only on the above mentioned
treatment planning parameters but also on dose per frac-
tion, target length in the longitudinal direction and average
dose rate. Taking all these issues into account, one can see
that estimation of the beam-on time is difﬁcult. Moreover,
the irradiation time is not known to the planner (for ver-
sions of up to 3.x) until ﬁnal dose is calculated, that is at
the end of treatment planning. In case where the dose dis-
tribution is not acceptable or the treatment time is too long,
one needs to change the treatment planning parameters (FW,
MF, PF) and start the whole procedure from the beginning.
This is cumbersome since the optimization of the plan takes
more than 2 h and it is not possible to make a copy of a
plan (except the newest version of the Tomotherapy software
(VoLO Technology) introduced in May 2012) or compare two
versions of the plan.19 It would be useful to know the beam-
on time in advance because it would reduce the workload of
the treatment planning unit. According to the manufacturer,
the irradiation time can be calculated based on the equation:
t = MF  · (TL + FW) · Df
FW · D˙ (1)iotherapy 1 8 ( 2 0 1 3 ) 201–208
where MF – modulation factor, FW – ﬁeld width, TL – target
length, Df – dose per fraction, and D˙ – average dose rate.
However, one does not know the exact dose rate during
plan optimization. Mackie et al.20 proposed a constant value.
For example, for prostate treatment it would be 4.8 Gy/min,
assuming exponential decay from an effective depth of 12 cm
and an effective attenuation coefﬁcient of 0.04 cm−1. This can
lead to some inconsistencies.
2.  Aim
The aim of this study was to propose a method of treatment
time computation based on empirical data gathered in our
institution. This analysis was performed for three cases – a
target volume covering the prostate alone, prostate with semi-
nal vesicles and that including prostate, seminal vesicles and
lymph nodes.
3.  Materials  and  methods
3.1.  Patients
This study included 10 patients treated for prostate cancer on
Tomotherapy in our institution in order to develop a correla-
tion model of beam-on time estimation. Then, 40 (treated on
Tomotherapy version 3.1.5.3) and 22 (treated on Tomotherapy
version 4.0.4.17) randomly chosen patients were used to verify
this model.
For all 72 patients, CT images (Somatom Sensation Open,
Siemens Corp.) were performed with slice reconstruction of
5 mm.  Ten patients for whom the model was built were
scanned only in a supine position with a knee-ﬁx (Sinmed
Corp.) immobilization system. However, the group of patients
that veriﬁed our model was scanned both in a supine (49
patients) and prone position (13 patients) with a belly-board
stand (Sinmed Corp.) The procedure before the CT was always
the same – patients were asked to empty the bladder 30 min
before the scanning and then to drink 500 ml  of water. No
preparations to empty the rectum (endorectal balloon or
enema) were used. All OARs and target contours were cre-
ated in the Eclipse 7.3.10 (Varian Corp.) treatment planning
system. CT scans as well as structure sets were exported
in DICOM format to the Hi-Art Tomotherapy planning sys-
tem. Prostate gland, seminal vesicles and pelvic lymph nodes
were delineated as a clinical target volume (CTV). For patients
from the correlation model, a margin of 1 cm was always
added to CTV to create a planning target volume (PTV). For
patients who veriﬁed the model, margins from 0.7 cm to
1 cm were used. The correlation model was based on two
cases: the ﬁrst (PTV1) included the prostate gland, seminal
vesicles, pelvic lymph nodes and a 1 cm margin; the other
one (PTV2) included only the prostate gland with a 1 cm
margin. However, in this study we veriﬁed our model for
three groups of patients who had: only prostate (10 patients),
prostate and seminal vesicles (38 patients) or prostate
gland, seminal vesicles and pelvic lymph nodes (14 patients)
irradiated.
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Table 1 – Values of planning parameters used to create eight different treatment plans. FW – ﬁeld width, PF – pitch factor,
and MF  – modulation factor.
Plan name FW PF MF planned MF actual PTV1
Mean ± SD
MF  actual PTV2
Mean ± SD
Reference 1.05 0.107 3.5 2.47 ± 0.32 2.26 ± 0.39
Default 2.5 0.215 2.5 2.01 ± 0.14 1.94 ± 0.22
FW = 1.05 1.05 0.215 2.5 2.05 ± 0.28 2.17 ± 0.14
FW = 5 5  0.215 2.5 1.86 ± 0.14 1.88 ± 0.13
PF = 0.107 2.5 0.107 2.5 1.89 ± 0.16 1.77 ± 0.15
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Whereas, the Pearson correlation coefﬁcient r is interpreted asPF = 0.43 2.5 0.43 2.5 
MF = 1.5 2.5 0.215 1.5 
MF = 3.5 2.5 0.215 3.5 
.2.  Treatment  plans  and  correlation  model
o build a correlation model of treatment time, the authors
erformed 160 treatment plans for 10 patients. Each patient
as considered twice – once PTV1 was a target volume, than
TV2. For each of these cases, eight treatment plans, which
aried in combination of planning parameters (FW = 1.05, 2.5,
 cm;  PF = 0.107, 0.215, 0.43; MF  = 1.5, 2.5, 3.5), were created. The
xact speciﬁcation of each plan is shown in Table 1. These
ata gave the information of how much the FW, PF and MF
nﬂuence the beam-on time. The speciﬁc and detailed descrip-
ion of patients and the methodology of generating treatment
lans for a correlation model was described in our previous
ublication.11 On the basis of these data, a correlation model
as built.
It is well known, that due to a helical irradiation in
omotherapy one of the most signiﬁcant parameter determin-
ng the beam-on time is the target length (TL).21 Taking this
nto account, a graph of beam-on time as a function of TL
as plotted for all 160 treatment plans. A linear trend func-
ion was drawn and the coefﬁcient of determination R2 and
he Pearson correlation coefﬁcient r were calculated for each
f the 8 trend lines corresponding to the adequate treatment
lan. Equations for each trend line were also determined and
fterwards used in a correlation model. However, this model
as not complete since PF and MF  may be chosen continu-
usly, contrary to FW that is a discrete parameter. It should be
oted that, to minimize the thread effect,12 it is advisable to
se discrete values of 0.43, 0.287, 0.215 or 0.107, . . ..  It has been
hown11 that for prostate cancer patients the treatment time
or PF = 0.215 and PF = 0.43 is almost the same. For this reason,
hose patients who  are planned with PF = 0.287 may be con-
idered as those with PF = 0.215. Due to this fact, correction
n the correlation model was only introduced for MF. For this
urpose, a graph of mean beam-on time as a function of MF
as plotted and a quadratic trend line was determined. This
as done only for the data gathered for PTV1 plans since the
rend line for PTV2 was analogical. Afterwards, an equation
hat corrected the beam-on time for MF  values (different than
.5, 2.5 and 3.5) was calculated.
All verifying 62 treatment plans were prepared in the same
anner – the dose to OARs was reduced to a minimum, while
he dose homogeneity in the PTV maintained between 95%
22,23nd 107%, according to the ICRU 50 and 62 reports. The
ose constraint for OARs was chosen individually for each
atient, based on their anatomical conditions. Some effort was
ade to keep the dose to PTV as homogeneous and conformal2.10 ± 0.13 2.02 ± 0.16
1.25 ± 0.06 1.31 ± 0.05
2.80 ± 0.21 2.64 ± 0.22
as possible, however, without violating DVH constraints stated
in the QUANTEC paper.24 Since we  used in this study a Hi-Art
Tomotherapy planning system version 3.1.5.3 (that has only 1
DVH point for optimization), we changed the constraint point
during the whole process of optimization – starting from high
doses toward low doses. The calculation grid size used for the
dose calculation was 0.254 cm × 0.254 cm × 0.50 cm (ﬁne). The
correlation model was built for the conventional 2 Gy per day
scheme of prostate cancer radiotherapy. Hence, in this study
the authors included only prostate cancer patients treated in
a single prescription dose level.
The authors tested two  groups of patients treated on dif-
ferent versions of Tomotherapy software: 3.1.5.3 (40 patients)
and 4.0.4.17 (22 patients). This was a must since the newer
version of HT has the minimum gantry period for treatment
mode equal to 12 rather than 15 s (as for the previous version).
Due to this fact, the irradiation time can be shorter. An attempt
was made to ﬁnd a simple solution of scaling the estimated
irradiation time in order to match the faster version of HT.
All treatment plans (62 in total) that were gathered to verify
the treatment time computation model were compared with
our estimation and with irradiation time calculated based on
Eq. (1) provided by the manufacturer.
4.  Results  and  discussion
A total of 222 plans were created, of which 160 were created
to build a model that predicts a treatment time for prostate
cancer patients when FW, PF, MF and TL were stated; and 62
plans were generated to verify this model.
4.1.  Building  a  correlation  model
In Fig. 1, a relationship of beam-on time as a function of TL
is presented for all treatment plans created with parameters
stated in Table 1. In this ﬁgure, linear trend functions were also
marked and the exact equation, the coefﬁcient of determina-
tion R2 and the Pearson correlation coefﬁcient r are presented
in Table 2. From these data, it can be seen, that the coefﬁcient
of determination is very high for most of the treatment plans.
Only for FW = 1.05, PF = 0.43 and MF = 3.5 is R2 below 0.99. This
means that, for example, for treatment plan MF = 3.5, 96.98%
of the variation in beam-on time is due to the variation in TL.a measure of the strength of linear dependence between these
two variables. A value of +1 or −1 implies that there is a per-
fect linear correlation between the two variables. In this study,
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Fig. 1 – Beam-on time as a function of treatment length (TL) for each treatment plan. FW – ﬁeld width, MF – modulation
factor, and PF – pitch factor.
Table 2 – Equation of the linear trend function, the
coefﬁcient of determination R2 and the Pearson
correlation coefﬁcient r for different treatment plan. TL –
target length and t – beam-on time.
Plan name Linear trend function R2 r
Reference t = 136.22·TL + 137.340 0.9975 0.9987
Default t = 27.278·TL + 97.906 0.9933 0.9966
FW = 1.05 t = 65.782·TL + 203.200 0.9781 0.9890
FW = 5 t = 14.037·TL + 82.225 0.9953 0.9976
PF = 0.107 t = 57.301·TL + 145.490 0.9977 0.9988
where t – treatment time estimated for MF:  1.5, 2.5 or 3.5,PF = 0.43 t = 24.551·TL + 114.300 0.9780 0.9889
MF = 1.5 t = 28.646·TL + 75.739 0.9976 0.9988
MF = 3.5 t = 35.294·TL + 151.800 0.9698 0.9848
the worst correlation was obtained for MF  = 3.5 since r = 0.9848.
Based on the data gathered in Table 2 one may notice that for
all treatment plans the strength of linear dependence is very
high.
Equations of linear trend functions can be used to estimate
the beam-on time for given treatment planning parameters
and TL. For example, the patient with a very small bladder had
to be irradiated on HT for the prostate and seminal vesicles,
where TL = 7.5 cm.  The plan was prepared for typical treat-
ment planning parameters used in our institution: FW = 2.5,
PF = 0.215 and MF  = 2.5, and the beam-on time obtained for
these data was approximately 5 min. However, for this plan
the dose to the bladder was very high, due to its small volume.
As shown,11 the most signiﬁcant reduction in dose to OARs
can be obtained for FW = 1.05, although this is combined with
the increase of irradiation time. With our simple method,
one does not have to make another plan to ﬁnd out what
the beam-on time will be for new planning parameters. One
needs only put TL into the formula from Table 2 for FW = 1.05and calculate the treatment time. From this formula, it follows
that the time will increase up to approximately 12 min. From
these calculations, one has to make the decision whether
to keep a short irradiation time with dose to the bladder
compromised or to spare bladder keeping in mind that the
longer beam-on time the more  intrafraction motion. With
this simple method, one may save time needed to optimize
the treatment plan for new FW parameter. Moreover, when
a change of FW is made the beamlets have to be calculated
one more  time, which also takes additional time. In our
institution, the beamlets are calculated only during the night
due to a large number of patients that need to be optimized
during working hours. Thus, in our case the plan for FW = 1.05
could not be optimized until the next day.
It is well known that increasing MF leads to a better sparing
of OARs. Thus, a correction in the model was introduced to
estimate more  accurately the beam-on time for MF  different
than: 1.5, 2.5 and 3.5. Based on the relationship of mean beam-
on time as a function of MF, a quadratic function was ﬁtted:
t = 48.19 · (MF)2 − 179.5 · MF + 432.6 (2)
where t – treatment time and MF  – modulation factor. However,
to ﬁnd a correction value for MF an equation should be used:
t = tMF − tx = 48.19 · [(MF)2 − (MFx)2] + 179.5 · (MFx − MF) (3)MF
tx – treatment time estimated for MF different than: 1.5, 2.5 or
3.5, MF – modulation factor equal to: 1.5, 2.5 or 3.5, and MFx –
modulation factor different than: 1.5, 2.5 or 3.5.
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Fig. 2 – Histogram of differences between real (from HT
system) and estimated (from correlation model) beam-on
time in seconds (A) and percentage (B) for the ﬁrstreports of practical oncology and 
Correction factor calculated based on Eq. (3) should be
dded to the treatment time estimated according to the data
rom Table 2. An exception should be made only for patients
n whom the prostate, seminal vesicles and lymph nodes
ere irradiated and a low MF  was used in the treatment
lan. This follows from the fact that for such a long PTV
here is no difference in treatment time between MF = 1.5 and
F  = 2.5.11
.2.  Veriﬁcation  of  the  correlation  model
ll patients that were used to verify the model were usu-
lly planned with FW = 2.5 (54 patients) and only 8 patients
ere planned with FW = 1.05. This is a common FW used for
rostate cancer patients25,26 and Whitelaw et al.27 stated that
or most cases a FW of 2.5 is the most suitable one. How-
ver, plans for FW = 1.05 are also found in the literature.28
hereas, for PF most patients were treated with PF = 0.287 (56
atients) and only 6 plans were generated for PF = 0.215. In the
iterature, most patients are also treated with PF = 0.287,25,26
lthough PF = 0.5 is also mentioned.28 In the case of MF, there
s a larger spectrum of values. Mean MF  for a group of ver-
ﬁcation plans was 2.54 (SD = 0.24) with a range from 2.1 to
.0. Those values agree with the ones found in the literature.
angen et al.25 used 2.5 as did Grigorov et al.,28 and Yuen
t al.29 used 3, whereas Fiorino et al.26 used MF  2–2.5 for sin-
le dose-level plans. Based on this knowledge, the veriﬁcation
roup was appropriate to verify the model, since it covered
he most suitable clinically used range of treatment planning
arameters.
The ﬁrst part of the veriﬁcation was based on the patients
lanned on the same version of Tomotherapy software (ver-
ion 3.1.5.3) on which the correlation model was build. For this
urpose, 40 randomly chosen patients treated in our institu-
ion were analyzed in terms of beam-on time. The authors
stimated the treatment time based on the correlation model
s well as on the basis of Eq. (1) given by the manufacturer.
hese data were than compared with the real time executed
n the HT unit. Fig. 2 presents histograms of the time dif-
erence, in seconds and percentage, for each method. These
ata showed that the estimation suggested by the manufac-
urer tended to underestimate the beam-on time on average by
2 s (Fig. 3). However, differences of up to 154 s were observed.
hereas, the estimation based on the correlation model over-
stimated the treatment time on average by 14 s (Fig. 3).
n Fig. 2B, an advantage of the correlation model might be
bserved, since the most frequent beam-on time differences
ere below 10% and the data were distributed almost sym-
etrically (skewness = −0.08), which might suggest a good
ssessment of our model.
The second part of the veriﬁcation was based on the
atients planned on the newer version of Tomotherapy soft-
are  (version 4.0.4.17) which has the minimum gantry period
or treatment mode equal to 12. This modernization short-
ns the beam-on time. This can be observed in Fig. 4, since
he time differences for the correlation model were shifted
oward larger discrepancies. The estimation based on the cor-
elation model overestimated the treatment time on average
y 87 s (Fig. 4). Whereas, the estimation suggested by the
anufacturer underestimated the beam-on time on averageveriﬁcation group of treatment plans.
by 8 s (Fig. 4). Due to the fact that the model overrated the
beam-on time approximately by 23%, the authors concluded
that it must be because of lower minimum gantry period and
scaled all the data from the model by this value. Corrected
values were presented in the form of histogram in Fig. 5A
and B and as a mean difference in treatment time with stan-
dard deviation (SD) in Fig. 4. The above mentioned ﬁgures
showed that after the introduction of a correction factor of
23% (because the estimated execution time was decreased
by 23%) both methods (correlation model vs. manufacturer’s
equation) were more  or less similar. However, in the model the
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Fig. 3 – Mean differences between real (from HT system)
and estimated (from correlation model) beam-on time in
seconds and percentage for the ﬁrst veriﬁcation group of
treatment plans.
Fig. 4 – Mean differences between real (from HT system)
and estimated (from correlation model) beam-on time in
seconds and percentage for the second veriﬁcation group of
treatment plans. For correlation model presented results
Fig. 5 – Histogram of differences between real (from HT
system) and estimated (from correlation model) beam-on
time in seconds (A) and percentage (B) for the second
veriﬁcation group of treatment plans.are before and after applying a correction factor.
SD for a mean treatment time difference is shorter. Knowing
that SD may be a measure of uncertainty, one could con-
clude that a correlation model better predicts the beam-on
time.
The authors found one publication related to the estima-
tion of the treatment time for patients treated on HT unit.
This study30 presented a method for estimation of the scaling
factor for prostate cancer patients, which is a patient-speciﬁc
parameter used to calculate the rotational period of the gantry
and, as a result, the treatment time. The results obtained inthis research are acceptable since the differences between
real beam-on time and the estimation were from −2.8% to
+7.1%. Those differences are smaller than in our study; how-
ever, Grigorov and Chow30 tested the methodology only on 10
patients. Moreover, this study included only patients irradi-
ated for prostate and seminal vesicle (without lymph nodes).
Whereas, our study is designed to estimate the treatment time
regardless of irradiated volume.
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.  Conclusions
his study proposed a novel method to estimate the beam-on
ime for prostate cancer patients treated on Tomotherapy. The
ethodology was based on empirical data and was suited for 2
ersions of HT unit – with minimum gantry rotation periods of
2 s and 15 s. The results are satisfying since for 62 treatment
lans our model disagreed with the HT software in 5 plans
 the disagreement of beam-on time was higher than 1 min.
hereas, for the equation provided by the manufacturer the
iscrepancy above 1 min  was observed in 16 cases. From the
ata, one may conclude that the model can better predict the
reatment time for a given TL, MF, FW and PF. This approach
s easy in use since all one needs to do is to apply the equa-
ions from the model into a spreadsheet, enter the treatment
lanning parameters and the length of the PTV to immediately
btain the estimation. This may save a lot of time when one
esitates which treatment planning parameters to use. The
uthors think that it may be a useful tool in clinical practice.
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